Early Development Led by the PCCTC, FDA Approval Now Sought for Apalutamide
October 12, 2017 | Media Relations
A new drug application (NDA) has been submitted to the FDA for apalutamide (ARN-509) for the treatment of non-metastatic castration-resistant prostate cancer (CRPC), according to Janssen Biotech, the manufacturer of the next-generation oral androgen receptor inhibitor.
Committed to world-class science!
Our services translate scientific discoveries into improved standards of care, ensuring efficient trial selection, reporting, site management, clinical operations and data analyses.